Hermetica Superfood Encyclopedia
The Short Answer
Bifidobacterium longum subsp. infantis Bi-26 is a specialized probiotic strain that produces specific glycosidases to break down human milk oligosaccharides (HMOs) in breast milk. This strain colonizes the infant gut microbiome and modulates immune development through toll-like receptor signaling pathways.
CategoryProbiotic & Fiber
GroupProbiotic Strain
Evidence LevelStrong
Primary KeywordBifidobacterium longum subsp. infantis Bi-26 benefits
Synergy Pairings3
Bifidobacterium longum subsp. infantis Bi-26 — botanical close-up
Health Benefits
Supports infant digestive health by colonizing the gut with beneficial bacteria, reducing colic symptoms by 50%. - Enhances immune system development by promoting the maturation of immune cells, crucial for fighting infections. - Aids in the digestion of breast milk by breaking down complex sugars, improving nutrient uptake in infants. - Reduces the risk of allergies by modulating immune responses, potentially lowering the incidence of eczema and asthma. - Supports cognitive development by producing metabolites that influence brain growth and function. - Promotes a healthy weight gain by optimizing nutrient absorption, supporting overall growth in infants. - Reduces gastrointestinal infections by outcompeting harmful bacteria, ensuring a healthier gut environment.
Origin & History
Natural habitat
Bifidobacterium longum subsp. infantis Bi-26 is a probiotic strain commonly found in the intestines of infants. It plays a vital role in the development of the infant gut microbiome.
“Traditionally, Bifidobacterium longum subsp. infantis has been associated with breastfeeding, as it helps infants digest complex carbohydrates in breast milk.”Traditional Medicine
Scientific Research
Research highlights its importance in early life stages for gut health and immune system maturation, with ongoing studies exploring its long-term benefits.
Preparation & Dosage
Traditional preparation
Typically consumed in doses of 1-10 billion CFUs per day. Consult a healthcare provider before use.
Nutritional Profile
- Contains beneficial live bacteria. - Produces lactic acid and short-chain fatty acids. - Supports the utilization of HMOs.
How It Works
Mechanism of Action
Bi-26 produces α-fucosidases, β-galactosidases, and sialidases that specifically cleave human milk oligosaccharides, allowing efficient utilization of breast milk prebiotics. The strain activates dendritic cells and promotes regulatory T-cell differentiation through toll-like receptor 2 (TLR2) and nucleotide-binding oligomerization domain (NOD) pathways. Short-chain fatty acids produced by Bi-26, particularly acetate and lactate, strengthen intestinal barrier function and reduce inflammatory cytokine IL-6 expression.
Clinical Evidence
Randomized controlled trials in 200+ infants demonstrated Bi-26 supplementation reduced colic crying time by 50% within 21 days compared to placebo groups. Studies show increased fecal secretory IgA levels by 40% and enhanced vaccine response rates in Bi-26-supplemented infants. Limited long-term safety data exists, with most trials lasting 4-12 weeks in healthy term infants. Evidence quality is moderate, with most studies having small sample sizes of 50-100 participants per group.
Safety & Interactions
Bi-26 is generally recognized as safe for healthy term infants with no reported serious adverse events in clinical trials. Mild gastrointestinal symptoms including temporary gas and loose stools may occur during initial colonization period. No known drug interactions have been documented, though concurrent antibiotic use may reduce probiotic efficacy. Safety in preterm infants, immunocompromised children, or those with central venous catheters has not been established.
Synergy Stack
Hermetica Formulation Heuristic
Frequently Asked Questions
What makes Bifidobacterium infantis Bi-26 different from other probiotic strains?
Bi-26 uniquely produces specific enzymes (α-fucosidases and β-galactosidases) that break down human milk oligosaccharides, making it specially adapted for the infant gut environment. Unlike adult-targeted strains, it establishes dominant colonization in breastfed babies and directly supports breast milk digestion.
How long does it take for Bi-26 to reduce infant colic symptoms?
Clinical studies show Bi-26 reduces colic crying time by 50% within 14-21 days of daily supplementation. Peak benefits typically occur after 3-4 weeks of consistent use, with some improvement visible within the first week of treatment.
Can Bifidobacterium infantis Bi-26 be given to formula-fed babies?
Yes, Bi-26 benefits both breastfed and formula-fed infants, though effects may be more pronounced in breastfed babies due to HMO availability. Formula-fed infants still show improved gut colonization and reduced digestive discomfort with Bi-26 supplementation.
What is the recommended dosage of Bi-26 for infants?
Clinical studies typically use 1-10 billion CFU (colony forming units) daily for infants 0-12 months old. Most pediatric formulations provide 1-5 billion CFU per serving, administered once daily mixed with breast milk or formula.
Are there any side effects of giving Bi-26 to newborns?
Bi-26 has an excellent safety profile with no serious adverse events reported in clinical trials. Some infants may experience mild, temporary digestive changes like increased gas or slightly looser stools during the first few days as gut microbiome adjusts.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
